Tag Archive for: Respiratory Syncytial Virus

Today the company announced that its respiratory syncytial virus (RSV) shot mRESVIA showed 50% efficacy in preventing RSV after 18 months.

A committee of outside experts to the U.S. CDC are set to vote on whether to expand the age group of adults who should receive respiratory syncytial virus (RSV) vaccines this year, as GSK battles rival Pfizer and new entrant Moderna to keep its top position in the market.

The agency approved a label expansion for GSK’s respiratory syncytial virus vaccine Arexvy, allowing its use in adults aged 50 through 59 years who have a medical condition that increases their risk of severe outcomes.

Moderna’s respiratory syncytial virus (RSV) vaccine mRESVIA has received FDA approval for use in adults aged 60 years and older, marking the first time that an mRNA vaccine has been approved for a disease other than COVID-19. This approval represents a significant development in the field and will likely encourage the use of mRNA technology across other disciplines, says GlobalData.

The FDA and CDC warned Thursday of a small increased risk of developing Guillain-Barré syndrome in older adults after immunization with respiratory syncytial virus vaccines from GSK and Pfizer.

The company said in a press release that the vaccine’s efficacy against RSV-associated lower respiratory tract disease with three or more symptoms was 77.8% through season two, compared with efficacy of 88.9% after the first RSV season, which led to the shot’s U.S. approval.

The profit was helped by cost cutting and some deferred payments, and the vaccine maker set out a commercial roadmap for its experimental respiratory syncytial virus (RSV) shot.

The company beat market estimates for fourth-quarter results today, and unveiled an upbeat forecast for 2024 and beyond on the ramp-up of its vaccines and cancer drugs pipeline, underscoring the benefits of its consumer health unit spin-off.

According to brokerage Oppenheimer, Moderna could have five products on the market by 2026.

The drug makers co-developed the RSV shot for infants and toddlers called Beyfortus, which has already been approved for use in the European Union and United States.